Table I.
Baseline characteristics of the unmatched and propensity score-matched patient groups
| Unmatched patients |
Propensity score-matched patients∗ |
|||
|---|---|---|---|---|
| SARS-CoV-2 positive patients n = 161 | SARS-CoV-2 negative patients n = 342 | SARS-CoV-2 positive patients n = 123 | SARS-CoV-2 negative patients n = 196 | |
| Age category–no (%) | ||||
| <50 y | 14 (8.7) | 89 (26.0) | 13 (10.6) | 19 (9.7) |
| 50–<70 y | 51 (31.7) | 138 (40.4) | 47 (38.2) | 80 (40.8) |
| ≥70 y | 95 (59.0) | 115 (33.6) | 63 (51.2) | 97 (49.5) |
| Female sex–no (%) | 72 (44.7) | 161 (47.1) | 56 (45.5) | 93 (47.4) |
| BMI–no (%) | ||||
| <18.5 | 7 (4.3) | 29 (8.5) | 6 (4.9) | 10 (5.1) |
| 18.5–<25 | 49 (30.4) | 117 (34.2) | 41 (33.3) | 65 (33.2) |
| 25–<30 | 46 (28.6) | 112 (32.7) | 39 (31.7) | 66 (33.7) |
| 30–<35 | 32 (19.6) | 49 (14.3) | 24 (19.5) | 38 (19.4) |
| 35–<40 | 12 (7.5) | 21 (6.1) | 10 (8.1) | 15 (7.7) |
| ≥40 | 5 (3.1) | 3 (0.9) | 3 (2.4) | 2 (1.0) |
| Missing | 10 (6.2) | 11 (3.2) | 0 | 0 |
| Current smoker–no (%) | 18 (11.2) | 47 (13.7) | 18 (14.6) | 33 (16.8) |
| Missing | 33 (20.5) | 71 (20.8) | 0 | 0 |
| Diabetes–no (%) | 44 (27.3) | 42 (12.3) | 22 (18) | 35 (18) |
| Hypertension–no (%) | 80 (49.7) | 105 (30.7) | 53 (43.1) | 87 (44.4) |
| Missing | 0 (0.0) | 13 (3.8) | 0 | 0 |
| Congestive heart failure–no (%) | 13 (8.1) | 19 (5.6) | 8 (6.5) | 13 (6.6) |
| Myocardial infarct–no (%) | 21 (13.0) | 24 (7.0) | 12 (9.8) | 19 (9.7) |
| Peripheral vascular disease–no (%) | 26 (16.1) | 40 (11.7) | 16 (13) | 27 (14) |
| Chronic pulmonary disease–no (%) | 20 (12.4) | 26 (7.6) | 10 (8.1) | 20 (10) |
| CVA–no (%) | 24 (14.9) | 31 (9.1) | 13 (11) | 21 (11) |
| Chronic renal disease–no (%) | 22 (13.7) | 25 (7.3) | 10 (8.1) | 16 (8.2) |
| Cancer–no (%) | 30 (18.6) | 123 (36.0) | 27 (22) | 47 (24) |
| Transplant–no (%) | 1 (0.6) | 7 (2.0) | 1 (0.8) | 1 (0.5) |
| Missing | 2 (1.2) | 2 (0.6) | 0 | 0 |
| Immunosuppression–no (%) | 10 (6.2) | 17 (5.0) | 9 (7.3) | 10 (5.1) |
| Missing | 0 | 6 (1.8) | 0 | 0 |
| ECOG score | ||||
| 0–1 | 93 (57.8) | 288 (84.2) | 92 (75) | 155 (79) |
| 2 | 26 (16.1) | 29 (8.5) | 21 (17) | 25 (13) |
| 3–4 | 30 (18.6) | 18 (5.3) | 10 (8.1) | 16 (8.2) |
| Missing | 12 (7.5) | 7 (2.0) | 0 | 0 |
| Charlson comorbidity index–median (IQR) | 4 (2–7) | 4 (2–6) | 4 (2–6) | 4 (2–6) |
| Missing | 0 (0.0) | 1 (0.3) | 0 | 0 |
| ASA classification–no (%) | ||||
| I–II | 60 (37.3) | 169 (49.4) | 54 (44) | 87 (44) |
| III–IV | 97 (60.2) | 170 (49.7) | 69 (56) | 109 (56) |
| Missing | 4 (2.5) | 3 (0.9) | 0 | 0 |
| Anesthesia–no (%) | ||||
| General | 118 (73.3) | 291 | 98 (80) | 156 (80) |
| Other (including spinal) | 43 (26.7) | 51 | 25 (20) | 40 (20) |
| Missing | 0 (0.0) | 0 (0.0) | 0 | 0 |
| Type of operation–no (%) | ||||
| Elective | 87 (54.0) | 252 (73.7) | 76 (62) | 131 (67) |
| Emergency | 73 (45.3) | 84 (24.6) | 47 (38) | 65 (33) |
| Missing | 1 (0.6) | 6 (1.8) | 0 | 0 |
| Surgical risk score–no (%) | ||||
| 1–2 | 42 (26.1) | 72 (21.1) | 35 (29) | 48 (25) |
| 3 | 64 (39.8) | 135 (39.5) | 47 (38) | 86 (44) |
| 4 | 36 (22.4) | 100 (29.2) | 31 (25) | 48 (25) |
| 5 | 10 (6.2) | 31 (9.1) | 10 (8.1) | 14 (7.1) |
| Missing | 9 (5.6) | 4 (1.2) | 0 | 0 |
BMI, body mass index; CVA, cerebrovascular accident; ECOG, Eastern Cooperative Oncology Group.
∗
Data for patients included in the propensity-score–matched analysis were multiply imputed.